ESR1 and breast cancer: Owing to shortages of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her-2), endocrino- and trastuzumab-based therapies that worked for other BC subtypes were no longer suitable for TNBC treatment [3].